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The emerging capabilities of checkpoint blockade immunotherapy to potentiate 
effective antitumor immune responses has galvanized the field of cancer treatment. Initial usage 
of checkpoint blockade immunotherapy has already shown great promise, driving increases in 
overall survival and progression free survival (PFS) in patients with non-small cell lung cancer 
and melanoma1-2. However, they are incompletely ineffective in different patients and cancer 
types3-5. Studies have shown that checkpoint blockade immunotherapy in combination with 
strategies to induce T cell targeting of tumor-specific antigens and mutation-associated 
neoantigens, demonstrates the ability to illicit stronger tumor regression6. Using an assay 
optimized by the Pardoll lab, we looked to identify TAA-/MANA-specific CD8+ TCRs in patients 
who successfully had complete tumor regression in response to checkpoint blockade 
immunotherapy, anticipating that there may be underlying patterns or preferences in T cell 
targeting of tumor antigens. Modeling for long-lived CD8+ T cell memory, we ran the FEST assay 
using TAAs and MANAs on CD8+ T cells isolated from 3-year post-treatment peripheral blood 
from metastatic melanoma patients who had complete responses to checkpoint blockade 
immunotherapy. We identified 7 antigen-specific CD8+ TCR clonotypes which contain 
specificities for TAA or putative MANA peptides. Interestingly, we observe multiple T cell clones 
with different underlying nucleotide sequences contributing to the same amino acid TCR 
sequence with typically one nucleotide TCR clone dominating contribution to the clonotype. 
Identified TCR clonotypes have specificities for antigens of recurrent mutations or mutations in 
proteins that carry prognostic value. We also have discovered the presence of our identified 
MANA-specific TCR clones in tumor infiltrating lymphocytes of melanoma patients from 
iii 
 
separate cohorts. Our data suggests the potential enrichment for TCRs which selectively 
recognize mutations in proteins that provide selective advantage or in proteins carrying 
passenger mutations. With the presence of both, functionally responsive TAA-specific and 
MANA-specific T-cells, in the long-lived CD8+ TCR repertoire of metastatic melanoma patients 
who had complete responses to immunotherapy treatment, our study demonstrates the 
importance of targeting both types of antigens in mounting an effective antitumor immune 
response.  
Primary Reader: Drew Pardoll M.D./Ph.D. 
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      Melanoma is the most aggressive form of skin cancer, although contributing to only 1% 
of total cancer cases, its worldwide incidence has been steadily increasing for the past 3 
decades9,10. Sun exposure and having fair skin are regarded as risk factors for developing 
melanoma, presumably due to mutations brought on by ultraviolet radiation induced DNA 
damage10,11. If caught and treated during early stages, melanoma patients have a 99% 5-year 
survival rate, in contrast to a 10-15% 5-year survival rate when caught at later stages12,13. 
However, with the emergence of checkpoint blockade immunotherapy as an effective cancer 
treatment for patients with metastatic melanoma, has resulted in dramatic increases in 
objective response rates (ORR), with 40-50% of metastatic melanoma patients seeing 
measurable tumor regression after receiving immunotherapy. In addition to increased ORR, 
duration of progression free survival of these patients has increased to about 12 months1. 
Despite the observed efficacy of checkpoint blockade immunotherapy, only a subset of patients 
respond favorably to treatment and achieve sustained tumor remission14. As the field of cancer 
immunotherapy continues its rapid expansion, it becomes imperative to characterize the nature 
of antitumor immune responses to address discrepancies in checkpoint blockade 
immunotherapy treatment responses15.  
An individual’s immune system is a highly capable defense system which enables the 
recognition and destruction of infected or otherwise foreign and transformed self cell. 
Generally, immunity consists of innate immune responses against nonspecific pathogen targets, 
and adaptive immune responses against targets with high specificity. Both arms working in 
concert in contributing to overall immune responses to foreign targets, adaptive components 
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such as T and B lymphocytes are primarily responsible for mediating activated immune 
responses against cellular targets with high degrees of specificity. Each T cell specificity is 
derived from the surface expression of unique T cell receptors (TCRs). Each TCR is a heterodimer 
of randomly expressed TCR-α and TCR-β chains, with variable regions from each chain 
contributing to antigen-binding specificity. Stochastic genetic recombination events drive 
expression and diversity of associated variable/diversity/joining genes for each TCR chain which 
then heterodimerize. This process can generate a TCR sequence from a repertoire of 1015 to 1520 
possible unique TCRs, allowing T cells to potentially recognize an immense spectrum of 
antigens17. After successful TCR formation, T cells further mature to express either CD4+ or CD8+ 
glycoproteins on their surfaces. Generally, CD4+ “helper” T cells aid in further immune activation 
while CD8+ cytotoxic T lymphocytes (CTLs) cellular killing abilities. CD4+ and CD8+ T cells 
disseminate throughout the body, continuing surveillance of antigenic peptides displayed on cell 
surface major histocompatibility complex (MHC) class I and class II molecules, respectively. After 
successful activation upon recognition of their TCR’s cognate peptide, CD4+ and CD8+ T cells can 
further differentiate into active effector or memory T cells16. With antigen availability being a 
determining factor, prolonged antigen exposure associated with development of this small 
subset of long-lived T cell memory. These memory T cells survive and circulate for extended 
periods of time, poised to react quickly upon repeated exposure to its cognate antigen16,30. 
T cells are key activators, regulators, and effectors of adaptive immune responses, 
however, their functionality hinge on their ability to activate upon recognition of cognate 
antigen-MHC complexes on cell surfaces. In addition to initial TCR and antigenic peptide-MHC 
binding, T cells need proper interaction of costimulatory receptors as well as activating 
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cytokines. Overall co- stimulation is a culmination of co-stimulatory and co-inhibitory receptor 
signals received when a T cell interacts with a target cells antigen-MHC complex. Depending on 
T cell lineage, various effector responses can occur. In terms of activated CTL effectors, they 
directly destroy cells display antigens for which their TCRs carry specificity. To prevent harmful T 
cell reactivity if expressed TCRs carry specificities for host, self-antigens, central and peripheral 
tolerance mechanisms play a fundamental role. A common immunotolerance mechanism is the 
expression of costimulatory molecules (co-inhibitory) which directly inhibit T cell activation. 
However, although this may be a normal process, tumors also use this mechanism as a means of 
suppressing activation of immunity against tumor antigens18,19.  
T cell immune-checkpoint  
T cell immune-checkpoint molecules are subsets of coinhibitory receptors/ligand 
complexes fundamental in downregulating T lymphocyte activation to induce tolerance. While 
fundamental in suppressing self-reactive lymphocytes under normal circumstances,  immune-
checkpoints can be overexpressed in tumors due to dysregulation brought on by malignant 
transformation, providing protection from antitumor T cell-mediated immunity. Subsequently, 
cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and programmed cell death 1 (PD-1) are 
amongst the most extensively studied T cell immune-checkpoint receptors and are the targets of 
current approved cancer immunotherapies18-20.  
Mainly affecting the priming step of naïve T cell activation occurring in lymphoid tissues, 
T cell expression of the inhibitory receptor CTLA-4, outcompetes its own costimulatory receptor 
CD28 with stronger binding of CD80/86 ligands expressed on antigen presenting cells. When 
CTLA-4 receptor binds its ligand, it triggers a cascade of inhibitory events within the T cell, 
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suppressing proliferation and inducing (anergy). While CTLA-4 mainly inhibits T cell priming 
steps in lymphoid tissues, the PD-1 receptor generally inhibits activation of mature T cells upon 
binding programmed cell death ligand 1 (PD-L1) expressed on target cell surfaces. CTLA-4 is 
considered constitutively expressed on T cells, however, PD-1 expression is induced upon T cell 
activation and it can also be expressed on lymphocytes other than T cells. T cell expression of 
PD-1 receptors is a hallmark of an “exhausted” state, characterizing T cell dysfunction. CTLA-4 
has been implicated in the induction of immunosuppressive tumor microenvironments. Both 
immune-checkpoint receptors work to inhibit T cell activation, inducing immunotolerance to 
tumor antigens and suppressing antitumor immune responses18-20. 
After initial discoveries that tumor take advantage of these checkpoints, 
immunotherapies were quickly developed using monoclonal antibodies (mAbs) which 
specifically target and block PD-1 and CTLA-4 checkpoint activation. Current approved 
checkpoint blockade immunotherapy treatments for metastatic melanoma patients include a 
nivolumab (anti-PD1 mAb) monotherapy or nivolumab/ipilimumab (anti-PD1/anti-CTLA4 mAbs) 
combinatorial therapy20. These treatments quickly achieved FDA approval, after displayed 
efficacy with about 50% of melanoma patients receiving measurable tumor regression in initial 
checkmate clinical trials14,20,21. However, despite initially taking the cancer field by storm, 
complications began to surface as checkpoint blockade immunotherapy was inconsistently 
effective across different cancer types and in some cases, treatment resistance developed5. As 
various biomarkers and characteristics are investigated for prognostic value in predicting tumor 
response to immunotherapy, focus has shifted back to the bread and butter of the immune 
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system, back to what makes it so special: the ability to discriminate between self and foreign 
antigens. 
Tumor-specific antigens vs. Tumor-associated antigens 
Possessing the potential to generate antigen-specificities from over a billion possible 
TCR sequences, endogenous patient T cell repertoires should conceivably be able to target 
expressed tumor antigens. As tumors continue accrue mutations to their genomic DNA, a 
hallmark of all cancers, their proteomic expression profiles inevitably change22. When displayed 
on cell surface MHC molecules, peptides derived from altered proteomes can potentially be 
recognized as immunogenic by endogenous T cells, eliciting an immune response.   
Known to express different antigen profiles than normal counterparts, expressed tumor 
antigens generally come in two flavors, tumor specific antigens (TSAs) and tumor associated 
antigens (TAAs). TSAs, also called neoantigens, are mutated forms of self-antigens, absent from 
normal antigen repertoire and specifically expressed in tumors23. As many of these neoantigens 
are due to nonsynonymous mutations in original genomic code of tumor cells, the term 
mutation-associated neoantigens (MANAs) is also often used, unless occurring in driver genes, 
MANAs are generally considered patient-specific24,25. In contrast, TAAs are self-antigens 
expressed by the tumor, but also expressed in normal cells to a limited degree. Examples of 
TAAs can be from germline/testis and differentiation proteins such as MAGE and MART-1, 
respectively, found overexpressed in melanoma26. Since melanoma antigen MART-1 and testis 
antigen MAGE were some of the first antigens found to be selectively expressed in melanoma, 
they were among the first targets of T cell therapy26. Also, with the observation that increased 
mutational load and/or neoantigen load is significantly associated with response to checkpoint 
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blockade immunotherapy, researchers have worked to identify neoantigen targets as well24,25. 
Studies using T cell targeting therapies against MANAs or TAAs have shown promise, however, 
cite the potential problem of treatment resistance, implying that immune antitumor 
mechanisms need further elucidation24-26. 
Antigen-specific T cells 
Due the breadth of their TCR repertoires and direct cytolytic function, CTLs expressing 
tumor antigen-specific TCRs have the ability to carry out direct killing of tumor cells27. Although 
evidence implies that this does indeed occur, tumors can avoid CD8+ T cell-mediated immune 
destruction by adopting a variety of immune evasion mechanisms, these of which can generally 
be divided into two groups: 1) the induction of an unresponsive, immunotolerant state and 2) 
evasion of activated immune effector cells19. As mentioned previously, current checkpoint 
blockade immunotherapies help overcome tumor-induced immunotolerance, unleashing T cell-
mediated immune responses. The next obstacle to producing effective antitumor immunity 
involves the second aforementioned cancer immune evasion strategy, which presents the 
problem of effectively targeting potentiated T cell immunity against the tumor.  With this is in 
mind, considerable effort has been invested in mapping intratumor mutation and neoantigen 
landscapes28,29. While antigen identification is undoubtedly important, it’s imperative to also 
identify the nature of activated T cell responses31. T cell activation effectively targets cancer 
destruction working under the assumption that endogenous TCR repertoires contain specificities 
for tumor antigens. Characterizing patterns or preferences in antigen targeting of endogenous 
TCRs, may provide invaluable information on what types of antigens illicit the most 
advantageous antitumor immune response24-27,29. 
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  Recent advances in next generation sequencing (NGS) and analytical techniques has 
allowed more accurate interrogation of expressed tumor antigens in addition to the T cell 
repertoire which recognizes them8. With these techniques, our lab has established the FEST 
assay which accurately and faithfully identify low-frequency TCR clonotypes which functionally 
expand to specific antigen stimulation8. This assay not only detects antigen-specific clonotypes 
at higher sensitivity and specificity than traditional immunoassays, but also produces a readout 
of unique TCR sequences which functionally respond31,32. Using amino acid and nucleotide 
TCRVβ CDR3 sequences to adequately barcode unique CD8+ TCR clones, abundance of each 
unique TCR are tracked in response to different peptide stimulation32. Since T cells 
fundamentally proliferate upon antigen-dependent activation, this assay identifies antigen-
specific TCRs based off clonal population expansion of TCR clonotypes in response to peptide 
stimulation.  
 Previous experiments used this assay design to identify MANA-specific TCR clones in 
NSLCLC patients who received anti-PD1 immunotherapy. Pairing FEST analysis with longitudinal 
whole exome sequencing data of NSCLC tumors, they were able to map tumoral loss of 
neoantigens that were specifically targeted by endogenous TCRs. They observed that 
neoantigen and mutational landscapes alone could not predict response to checkpoint blockade 
immunotherapy, implying that antigen quality have more influence over antigen quantity8.  
The wealth of information produced while performing this assay, presents the unique 
opportunity to interrogate TCR-recognized tumor antigens as well as the functionally responding 
T cell repertoire. Not only can this information be used to evaluate TAA versus MANA CD8+ TCR 
targeting, but also evaluate motifs enriched in identified antigen-specific TCRs. Differentiation 
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into long-lived CD8+ memory T cell is characteristic of CD8+ T cells functionally responding 
recognition of its TCR’s cognate antigen16,30.  Evaluating the tumor antigen-specific T cell 
repertoires isolated from peripheral blood samples collected long after their last 
immunotherapy treatment, enables us to interrogate long-lived CD8+ memory T cells. 
Interrogating long-lived antigen-specific TCR repertoires from patients who had complete 
responses to immunotherapy, enables us to potentially further characterize these reactive TCRs 












B. Project Aims 
I. Identify putative mutation-associated neoantigens (MANAs) expressed in tumors of 
metastatic melanoma patients.  
II. Identify TCRVβ CDR3 sequence clones which functionally expand to specific MANA- or 
TAA-peptide stimulation. 
III. Further characterize antigen-specific TCR clonotypes based on amino acid and/or 
nucleotide TCR sequences. 
• Assess potential differences in characteristics between MANA/TAA specific TCR 
clonotypes. 
IV. Identify intratumoral expression of immunological markers to phenotypically assess the 









C.  Methods 
Patient Samples 
Melanoma patients with pathologic complete tumor responses to checkpoint blockade 
immunotherapy were selected from a cohort of metastatic melanoma patients enrolled in 
J13139 tissue collection protocol at Johns Hopkins Hospital who received standard of care 
treatments with PD-1 (nivolumab) monotherapy or PD-1 and CTLA-4 (Nivolumab and 
ipilimumab) combinatorial therapy. Selection was also based on availability of initial pre-therapy 
tumor specimens and frozen PBMCs from a shared timepoint post therapy. In compliance with 
HIPAA regulations and protocol guidelines, all patient information (name, age, sex, race, 
comorbidities, etc.) was de-identified or not given to us. 
Per clinical study protocol guidelines, patient tumors were resected pre-treatment 
(when applicable), while blood was drawn at various timepoints during and after checkpoint 
blockade immunotherapy. For uniformity, patients with both pre-treatment tissue samples and 
a 3-year post-treatment blood draw were included. Study investigators collected whole blood 
purple top EDTA tubes and processed the same day for PBMC isolation. PBMCs were isolated 
using Ficoll-Paque (Sigma-Aldrich) protocols solution and stored in 10% DMSO at -80°C. 
MANA and TAA selection  
Whole exome sequencing (WES) of matched patient tumor/normal specimens was performed 
using PGDX ImmunoSELECT™-R platform (Baltimore, MD).  ImmunoSELECT™-R analysis and 
bioinformatics pipeline identified somatic nonsynonymous mutations (SNPs/insertions/deletions), 
from which candidate putative neoantigen peptides (8-11 amino acid length) were selected. 
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WES data also included genotyping of HLA-alleles, allowing for accurate prediction of MHCI 
binding of putative neoantigen peptides. Neoantigen peptides were excluded if classified as 
non-binders to patient MHC I molecules (netMHCpan) or if IC50 <50nM. Top 10 candidates for 
each representative HLA-allele then selected based on ranking of associated somatic mutation 
frequency in SKCM tumors from TCGA database. Selected peptides are our putative MANA 
peptides. 
 We selected validated TAA peptides of known melanoma TAA proteins (gp100, MAGE-
A3, Mart-1, Tyrosinase, PMEL) from online immune epitope database and analysis resource 
(iedb.org). Validated TAA peptides was based on number of positive results (n ≥ 5) from T cell 
and/or MHC binding assays. Candidate TAA peptides were ranked based on how many previous 
studies they were tested in (n ≥ 5). Top 10 candidate TAA peptides for each patient HLA-allele 
restriction were selected for synthesis. All peptides were synthesized using Sigma-Aldrich 
PEPscreen® platform (St. Louis, MO) as lyophilized peptides, which were dissolved in minimal 
DMSO and resuspended as 100 g/mL aliquots in AIM V media, and stored at -80°C. 
10-day T cell culture 
Each plate only contained T cells from one patient. T cells were isolated from frozen 
patient PBMC samples using EasySep Human T Cell Enrichment Kit and EasySep purple magnet 
(Stemcell Technologies; Vancouver, Canada). T cell and a non-T cell lymphocyte fractions were 
washed and resuspended at a concentration of 2.0 x106 cells/mL in AIM V media (50 g/ml 
gentamicin). Non-T cell fractions were irradiated at 3,000 -rads and washed to prevent 
proliferation and overcrowding. On a 96 well tissue culture-treated plate, irradiated non-T cell 
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and T cell fractions were added at a 1:1 ratio to a final volume of 250 uL per well. Before plating, 
an addition well’s equivalent of T cells is frozen down as baseline pre-culture reading. 
Representative MANA, TAA, CEF pool, SL9 peptides were individually added to separate wells at 
a final well concentration of 1ug/mL, leaving one well peptide-free. CEF pool was used as a 
positive control, while SL9 of irrelevant HLA-type was used as negative priming control. On day 3 
half of well culture media is replaced with fresh AIM V serum free medium (50 g/ml 
gentamicin) (ThermoFisher) along with addition of cytokines IL-2 (Chiron, IL-7 (Miltenyi), and IL-
15 (Peprotech) for final well concentrations of 50 IU/mL, 25ng/mL, and 25 ng/mL respectively. 
On day 7, half media was replaced again with fresh AIM V (50 g/ml gentamicin) along with IL-2, 
IL-7, IL-15 for final well concentrations of 100 IU/mL IL-2, 25ng/mL IL-7, 25 ng/mL IL-15. On day 
10, CD8+ T cells were isolated from T cell cultures using EasySep Human CD8+ T cell Enrichment 
Kit EasyPlate EasySep Magnet (Stemcell Technologies).  
DNA extraction was performed on isolated CD8+ T cells using QIAamp DNA micro kit and 
protocol (Qiagen). Extracted CD8+ T cell DNA frozen at -80°C and sent to Adaptive 
Biotechnologies immunoSEQ® (Seattle, Washington) for TCRVβ CDR3 sequencing. 
Tumor infiltrating lymphocyte extraction 
Resected pre-treatment formalin-fixed paraffin-embedded (FFPE) tumor sections were 
fixed onto positively charged slides (5-10 slides). Pathologist identified tumor infiltrating 
lymphocytes from hematoxylin and eosin (H&E) stained slides. Using H&E stained slides as a 
template, infiltrating lymphocytes were scraped from FFPE unstained positively charged slides 
into 1.8mL conicals, from which DNA extraction was performed using High Pure FFPET DNA 
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Isolation Kit (Roche). Extracted DNA stored at -80°C prior shipping to Adaptive Biotechnologies 
immunoSEQ® (Seattle, Washington). 
Biostatistical Analysis of significant antigen-specific expansions 
With T cells from only one patient tested per plate, analysis of antigen-specific 
expansions is done per plate. TCRVβ CDR3 amino acid and nucleotide sequencing data was 
obtained through Adaptive Biotechnologies Immunoseq® platform and used to barcode unique 
TCRs clonotypes.  Fisher’s exact test was used to compare relative enrichment of productive TCR 
templates between a peptide condition and control well (no peptide) condition that received – 
peptide/ + cytokine stimulation. With Benjamin-Hochberg procedure, p-values were adjusted to 
account for baseline threshold (n=1 TCR sequence template (nucleotide or amino acid 
sequence)), odds ratio threshold (OR=5), and normalized expansion compared to those of every 
other well condition (FDR threshold < .05). TCR clonotypes which satisfy these conditions are 










Mutagenic load, neoantigen load 
Patient whole exome sequencing data provided information on mutational and 
neoantigen landscapes of patient’s tumors before receiving checkpoint blockade 
immunotherapy. Distinct variation in mutational and neoantigen load was observed in the three 
melanoma patients tested. Patient 1 possessed the most natural germline variation (32,392 
germline SNPs) while also expressing considerably more somatic mutation (1,422 somatic 
sequence alterations) than the other two patients (292 and 218 somatic sequence alterations) 
(Table 1). Little to no variation in gene copies were seen in patients 1 and 2 (0 and 2, 
respectively), while 49 copy number variations were seen in patient 3. Interestingly, patient 3 





# of Somatic 
Sequence 
Alterations 




Patient 1 49% 1,422 0 32,392 
Patient 2 66% 292 2 30,408 
Patient 3 41% 218 49 28,213 
Table 1. Mutational and Neoantigen Tumor Landscape: # of somatic sequence alterations represent nonsynonymous 
genetic mutations in single genes resulting our candidate neoantigens from which we selected putative MANA-
peptides (8-11 amino acid length). 
As detailed in methods, Immunoselect-R platform accurately identifies somatic 
mutations and evaluates expression of neoantigen peptides based on predicted binding to 
patient HLA-allele restrictions. Our selected putative MANA-peptides, along with HLA-matched 
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TAA peptides were used to culture autologous T cells. Due to variation in T cell abundances 
between patient PBMC samples, number of MANA/TAA peptides conditions tested in each 
patient T cell culture differed (Supplement Tables 1-4).  
 
Antigen-specific TCR clones 
NGS data of TCRVβ CDR3 region genes was used to barcode unique TCR sequences at 
the amino acid and nucleotide levels. Using amino acid sequences, we tracked the template 
abundance of each unique TCR clonotype across different peptide well conditions after 10-day 
culture. We accurately identified significantly expanded TCR clonotype to specific peptide 
conditions using our optimized biostatistics analytic platform as stated in methods.  
Significant antigen-specific expansions of CD8+ TCR clonotypes were observed in T cell 
cultures from one (patient 3) of the three patients (possible reasons for this in discussion). The T 
cell culture for patient 3 stimulated with 62 different MANA/TAA-peptides, from these, 6 MANA 
and 3 TAA peptides produced functional expansions of 11 unique antigen-specific TCR amino 























































































Table 2. Antigen-specific TCR clonotypes from patient 3: 7 MANA-specific and 4 TAA-specific TCR clonotypes were 
produced after T culture with associated tumor peptides. Point mutation denotes single amino acid substitution 
resulting from nonsynonymous nucleotide mutation. Mutation frequency is percentage of mutated reads at that 
given position. Sum frequency shows the percentage of total TCR reads from the associated peptide culture well that 
is due to the given antigen-specific TCR clonotype. Fold change quantifies the antigen-specific expansion of the given 







MANA-specific TCR clones  
6 of the 52 tested MANA-peptides resulted in significant antigen-specific expansions of 
7 TCR amino acid sequence clonotypes (Supplementary Figures 1-6). Antigen-specific TCRs 
recognized MANA-peptides from 5 of 6 patient HLA-allele restrictions. Many of the TCR-
recognized MANAs resultant from nonsynonymous mutations in proteins (HUWE1, SEMA5A, 
ZHX3, DLGAP1, TTN) which have been identified to have various clinical and pathological 
relevance in melanoma patients and are addressed later in discussion.  
Interestingly, 2 separate TCR clonotypes significantly expanded in the same HUWE1 
MANA-peptide culture (115S>F, HLA-A*2:01), while Single populations of TCR clonotypes 
expanded in other MANA-peptide cultures. The HUWE1 MANA-specific TCR clonotypes 
combined for the highest frequency of all identified antigen-specific TCRs (measured individually 
in their associated peptide cultures), making up .79% of the total productive TCR templates in its 
culture well. However, when analyzed individually, TTN MANA-specific TCR was observed at the 
highest frequency (.572%). When cultured with its cognate TTN MANA-peptide (4247E>K, HLA-
C*8:02), it produced the largest clonal antigen-specific TCR expansion in terms of raw 
abundance and amplification (82 templates and 42-fold change from control). Interestingly, of 
the MANAs which produced antigen-specific TCR clones, highest mutation frequency was also 
observed at the loci producing the TTN MANA. The TTN MANA-specific TCR clone was also 
calculated to have the most statistically significant antigen-specific expansion (p>.10-16), 
followed by SEMA5A MANA-specific TCR clone (p>.10-7). Multiple TCR clonotypes specifically 
recognizing the same HUWE1 mutation, and strong clonal expansion of the TTN MANA-specific 
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TCR clonotype, suggests possible preference or importance in T cell targeting of these proteins 
or recognized peptide motifs.  
TAA-specific TCRs  
Since validated TAA peptides were lacking from other HLA-alleles, only HLA-A*2:01 
restricted TAA peptides were tested in patient 3 T cell cultures. 3 of the 10 TAA peptide cultures 
resulted in expansion of 4 unique TCR amino acid sequence clonotypes (Supplementary Figures 
7-9). Again, we observed 2 different TCR clonotypes significantly (p > .001) expand in the same 
MART-1 peptide culture, while single TCR clonotypes expanded to 2 separate PMEL peptides 
(Table 2). As seen previously, two separate TCR clonotypes carrying specificity for the same 
peptide (MART-1) may demonstrate importance of targeting these antigens or recognized 
peptide motifs.  
Nucleotide TCR sequences 
Since multiple nucleotide (nt) sequences can encode for the same amino acid TCR 
clonotype, we identified true expansions of single TCR clone populations using their underlying 
TCRVβ CDR3 nt sequences. We found for the majority of antigen-specific TCR sequence 
clonotypes, multiple clonal populations of different nt sequences encoded for the same amino 
acid TCR sequence. Despite multiple TCR nt sequence clones encoding for the same amino acid 
sequence, one nt TCR clone seemed to dominate expansions of associated antigen-specific TCR 
clonotypes. Repeat FEST analysis using nt TCR sequences confirmed antigen-specific expansions 
in 10 of the 11 previously identified TCR clonotypes stemmed from a single TCR clone (Table 3, 








# Unique nt 
TCR clones 
MANA HUWE1 CASSVGKGLGTEAFF 2 
MANA HUWE1 CASSPIAWDRDNSPLHF 1 
MANA SEMA5A CASSHSGALNTEAFF 2 
MANA ZHX3 CASSLALSETNNYGYTF 3 
MANA DLGAP1 CASSYLTGELFF 3 
MANA CPAMD8 CASSFRMPEAFF 1 
MANA TTN CASSLLGGNQPQHF 5 
TAA MART-1 CSAREGTANTEAFF 1 
TAA MART-1 CASSTSHLGWGYTF 1 
TAA PMEL CASSPGQGSSGNTIYF* 3 
TAA PMEL CASSKQGEGEKLFF 1 
Table 3. Nucleotide TCR sequence clones: Contribution of different nucleotide TCR clones to the same amino acid 
TCR. *= Expansion of single T cell clone not confirmed by nt TCR analysis 
 
MANA-specific versus TAA-specific TCR clones 
 Average fold change of MANA-specific TCR clones (FC = 19.71) was higher than that of 
TAA-specific TCR clones (FC = 13), suggesting slightly stronger strength of response. More 
contributing nucleotide TCR clones tended to contribute to the same MANA-specific amino acid 
TCR clonotype as compared to number of contributing TAA-specific clones, with an average of 
2.4 clones contributing to each MANA-specific TCR clonotype while an average of 1.5 clones 
contributed to TAA-specific TCRs. MANA-specific TCRs used TCRVβ27 the most, while TAA-
specific TCRs were widely distributed (Figure 1). Future directions of this study will further 
evaluate differences between MANA-specific and TAA-specific TCRs. We will determine motifs 




Figure 1: TCRVβ gene usage in antigen-specific TCRs. Using underlying nucleotide TCR sequences, the different clonal 
populations generated from each TCRVβ gene was summed. 
 
Tumor-infiltrating T cells 
 NGS data of patient 3 tumor infiltrating T cells from showed highest usage of the TCRVβ 
20 gene, followed by TCRVβ 06, TCRVβ 07, and TCRVβ 05 genes respectively (Supplementary 
Figure 10). Unfortunately, we could not locate peripherally identified antigen-specific TCRs, in 
autologous tumor specimens, though this could be due to several reasons as mentioned later in 
discussion.  
Using the adaptive biotech Immunoseq platform to cross-reference our TCR sequences 
in other published studies that used the Immunoseq platform, we identified DLGAP1 MANA-
specific TCR sequence was found infiltrating pre- or post-immunotherapy treatment tumor 
specimens in 4 of 40 melanoma patients from Dr. Ribas’ melanoma immunotherapy cohorts at 






























melanoma patients (7 of 40 patients) from Ribas’ cohorts37,38. In contrast to the DLGAP1-MANA 
TCR, we were able to observe the presence of TTN MANA-specific TCR sequences in matching 
pre- and post-immunotherapy patient tumor specimens, in some cases increased frequency was 
seen in matching post-therapy tumors (Figure 2). 
 
Figure 2: Frequency of CASSLLGGNQPQHF TCRVβ CDR3 sequences in other patients: TCR sequences from 
pre- and post-immunotherapy tumor infiltrate in melanoma patients from cohorts operated by Antoni Ribas 
M.D., Ph.D. at UCLA. Sequence was found in samples from 11 of 40 patients, and in 5 of these 11 patients 


































While many studies have investigated patient antitumor responses to checkpoint 
blockade immunotherapy in the context of autologous tumor antigen expression or CD8+ T cell 
repertoire, there are few which simultaneously evaluate both. Using our specialized FEST assay, 
we characterized functionally responsive CD8+ T cells concurrently with their native TCR antigen-
specificity.  
Failure to identify antigen-specific expansion in T cell cultures from two of the 
melanoma patients could be due to the lower number of peptides tested in their cultures due to 
lower T cell yield from PBMC samples (42 and 15 peptides tested in patients 1 and 2 
respectively, compared to 65 peptides tested in patient 3). Since FEST analysis evaluates plates 
individually, and peptides conditions are not tested in duplicate (due to limited patient 
samples), statistical power to detect significant antigen-specific expanded T cell clone 
populations is generated, in part, by the number of different peptide conditions tested per 
plate.  
T cell cultures from patient 3 shows the presence of TAA- and MANA-specific CD8+ T 
cells peripherally circulating 3 years after their last cycle of immunotherapy treatment. After 
failing to locate our identified antigen-specific TCRs within autologous tumor infiltrate, we 
speculate that adequate TCR sequencing read depth was not reached in isolated TIL DNA34. 
Repeat TCR sequencing of more appropriately stored and processed tumor specimens may 
provide sufficient read depth, allowing for higher accuracy in TCR sequencing. We did however, 
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locate a few of our identified antigen-specific TCR sequences in the tumor infiltrate of other 
melanoma patients from a separate cohort, which will be discussed shortly. 
Many of the MANA peptides which produced antigen-specific TCR expansions were 
derived from proteins with various clinical or pathological relevance to melanoma. With this 
respect, TCR clonotypes carrying specificities to DLGAP1, TTN, and HUWE1 MANAs will be 
discussed further.  
DLGAP1 encodes for guanylate kinase-associated protein, discs large-associated 
protein1, which primarily functions as a scaffold protein in neuronal synapses, where it 
contributes to homeostasis of synaptic excitation through regulation of post-synaptic Ca2+ 
levels35. A study analyzing single nucleotide polymorphisms (SNPs) of germline susceptibility 
genes in 891 melanomas, DLGAP1 was found to be one of the two germline genes where SNPs 
significantly predict decreased recurrence-free survival and overall-survival in metastatic 
melanoma patients36. As of our DGLAP1-MANA may potentially be displayed in two different 
patient HLA-allele restrictions (711 E>G, HLA-C*4:01 or HLA-C*8:02), this may show possible 
preference for presentation of this antigen. We also detected the resulting DLGAP1 MANA-
specific TCRVβ CDR3 amino acid sequence (CASSYLTGELFF) in tumor specimens of other 
melanoma patients from a separate melanoma cohort. Although observed at low frequencies in 
these patients (<.001% of all productive TCR templates), the presence of MANA-specific TCR 
sequences signifies potential shared MANA expression, which are generally considered to 
patient-specific25.  
TTN, the largest gene in the human genome, encodes for the protein titin (connectin), 
which is involved with contraction of striated muscle39. Stimulation with TTN-MANA peptide 
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(4247E>K, HLA-C*8:02 restricted) produced the largest and most significant TCR clone expansion 
of all MANA-/TAA-specific TCR clones. High somatic mutation frequency (32%) at the same 
location, alongside intense clonal expansion of its antigen-specific TCR clonotype 
(CASSLLGGNQPQHF), may signify potential T cell preference in recognizing the TTN protein or 
this MANA. A meta-analysis performed on tumors from 241 melanoma patients found the TTN 
gene to be the most significantly associated mutated gene (64.6%, p=.009) in tumors also 
containing BRAF mutations40. Since up to 60% of melanoma patients have tumors with BRAF 
mutations, these findings suggest potential overlap of acquired somatic mutations in the TTN 
gene between patients41.  
 HUWE1, an E3 ligase, primarily functioning in polyubiquitinating anti-apoptotic protein 
MCL1 for subsequent degradation, has recently identified as a tumor suppressor gene in colon 
cancer42,43. Mutations in HUWE1 may be highly penetrant in tumor distribution, as it may 
provide critical survival advantages for the tumor. We observed two separate TCR clonotypes 
expand in the same HUWE1 MANA-peptide culture, producing the highest cumulative frequency 
of all expanded antigen-specific TCRs, suggesting the importance of developing two separate 
CD8+ T cell clones against this HUWE1 mutation. Although we could not locate these TCR 
sequences in Ribas’ cohort, it recognizes a nonsynonymous mutation which has previously been 
identified to occur in melanoma (115S>F)44. Since this MANA peptide is presented in context of 
HLA-A*2:01 restriction, one of the most commonly expressed HLA-alleles in humans, there is 
increased possibility that other patients display the same MANA-peptide and can be recognized 
by similar/same sequences as our identified TCR clonotype.  
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For TAA-specific TCR clonotypes, two separate amino acid TCR sequence clones 
significantly expand to the same MART-1 peptide (HLA-A*2:01) while single TCR clonotypes 
expanded in two different PMEL (gp100) peptide cultures. Our identification of TAA-specific 
CD8+ T cell clones provides insight on antitumor TCR specificities in patients who receive 
combined checkpoint blockade immunotherapy and TAA T cell targeting vaccines.  
In addition to identifying TAA- and MANA-specific amino acid TCR clonotypes, we 
highlight the observation of multiple clonal T cell populations of differing underlying nucleotide 
sequences contributing to the same encoded amino acid sequence, with one nt TCR clone 
dominating in contribution to antigen-specific expansions of the same amino acid TCR 
clonotype. We speculate that the presence of multiple CD8+ T cell clones carrying the same TCR 
specificity may display a certain level of TCR target recognition preference in types of antigens 
displayed on MHC molecules. Amino acid TCR sequences which recognized clinically relevant 
peptides, HUWE1, DLGAP1, TTN, MART-1, and PMEL all received contributions from least 3 
populations of different nt TCR sequence clones. 
In summary, we demonstrate the presence of CD8+ T cells targeting both types of tumor 
antigens, TAAs and MANAs, in circulating peripheral blood of patients 3 years after their last 
treatment with checkpoint blockade immunotherapy. Recognizing that CD8+ T cell memory 
develops after prolonged antigen stimulation and resultant CD8+ T cell activation, our 
functionally expanded TCR clonotypes to tumor antigen stimulation may represent long-lived 
antitumor CD8+ T cell memory. The identification of these tumor antigen-specific CD8+ TCRs in 
patients who had complete responses to immunotherapy, suggests that effective antitumor 
immune responses have endogenous CD8+ TCR repertoire specificities for both TAAs and 
26 
 
MANAs. With multiple TCR amino acid clonotypes and multiple contributing nt TCR clones 
functionally carrying specificities for tumor antigens, we speculate that these may be 
characteristics of the magnitude of T cell expansion. The breadth of tumor antigen recognizing 
TCRs and the clinical relevance of the proteins they’re derived from, may imply strength and 
persistence in T cell targeting of these antigens. We also demonstrate TCR recognition of a 
recurrent melanoma mutation (HUWE1, 115S>F) and presence of MANA-specific TCR sequences 
infiltrating tumors from different patients.  
Cancer immunotherapy continues to be one of the most rapidly expanding cancer 
research fields, with focus shifting towards targeting tumor antigens to synergistically activate 
immune responses. However, not all tumor antigens are created equal, to be a bona fide tumor 
regression antigen, it must fulfill specified requirements: 1) Selectively expressed in tumor 2) 
Shared between patients 3) Persist despite immune pressure45. Although more validation 
studies are required, our initial observations of patient antigen-specific TCR clonotypes, show 








F. Future Directions 
 After the identification of antigen-specific TCRs which recognize TAAs and MANAs, we 
will use software developed by our lab (IMMUNOMAP) to assess amino acid peptide motifs they 
recognize.  
We also hope to repeat the FEST assay with available PBMCs from equivalent timepoints 
in patients which we failed to detect functional T cell expansions. To validate MANA-specific TCR 
clones, we will stimulate patient 3 T cells with wild-type peptide forms. We also plan on 
acquiring PBMC samples from the same patients at different timepoints, so that we may map 
the frequency of our antigen-specific TCR clones throughout the patient’s course of 
immunotherapy. 
We will also assess immunological markers expressed in the tumor microenvironment, 
using immunohistochemistry of tumor specimens. These markers will help determine what 
immune checkpoints were active in tumor environment. Staining will determine differentiation 
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H. Supplementary Tables 
 








Melanoma antigen recognized by T-
cells 1 (MART-1) 
AAGIGILTV HLA-A*2:01 
A201_2 




Melanoma antigen recognized by T-
cells 1 (MART-1) 
ALMDKSLHV HLA-A*2:01 
A201_4 Tyrosinase precursor MLLAVLYCL HLA-A*2:01 
A201_5 Tyrosinase YMDGTMSQV HLA-A*2:01 
A201_6 Cancer/testis antigen 1 SLLMWITQC HLA-A*2:01 
A201_7 MAGEA1 KVLEYVIKV HLA-A*2:01 
A201_8 Melanocyte protein PMEL (gp100) ITDQVPFSV HLA-A*2:01 
A201_9 Melanocyte protein PMEL (gp100) KTWGQYWQV HLA-A*2:01 

























































































































































































































































































































































































YSFSRHLYSF HUWE1 EYSFSRHLYS[S/F]IEHLTTLLAS 
P3_22 HLA-B*14:02 NRRLKHFL LRCH4 NLSNRRLKHF[P/L]RGAARSYDLS 




SASPHPCSSPL PRDM2 PSSSASPHPC[P/S]SPLSNATAQS 




MPFFTARL UBOX5 ALASTLGSMP[S/F]FTARLTRGQL 
P3_27 HLA-B*14:02 LRFLHTRL KCNS3 SVDQSTLLRF[P/L]HTRLGKLLTC 
P3_28 HLA-B*14:02 LRFLHTRLGKL KCNS3 SVDQSTLLRF[P/L]HTRLGKLLTC 
P3_29 HLA-B*14:02 HKMYREQINL FAM20A NRRHKMYREQ[M/I]NLTSLDPPLQ 
P3_30 HLA-B*14:02 SRHLYSFIEHL HUWE1 EYSFSRHLYS[S/F]IEHLTTLLAS 
P3_31 HLA-B*51:01 YSFSRHLYSFI HUWE1 EYSFSRHLYS[S/F]IEHLTTLLAS 
P3_32 HLA-B*51:01 CPFGAESNWSL TNKS1BP1 QGQGSQLALD[R/C]PFGAESNWSL 
P3_33 HLA-B*51:01 VPSKVAEVI USP32 IREVLGDGVP[P/S]KVAEVIYCSF 
40 
 
P3_34 HLA-B*51:01 VPSKVAEV USP32 IREVLGDGVP[P/S]KVAEVIYCSF 
P3_35 HLA-B*51:01 MPRLVSYHGCV KLHL24 IITGVAAMPR[P/L]VSYHGCVTIH 
P3_36 HLA-B*51:01 LPLTMTSV ZHX3 QATSSPLPLT[V/M]TSVPKQPGVA 
P3_37 HLA-B*51:01 SPLPLTMTSV ZHX3 QATSSPLPLT[V/M]TSVPKQPGVA 
P3_38 HLA-B*51:01 FSLEPKFAKTI DHX33 TPMGRKMAAF[P/S]LEPKFAKTIL 
P3_39 HLA-B*51:01 MPGFFVPTV FOSB ECAGLGEMPG[S/F]FVPTVTAITT 
P3_40 HLA-C*04:01 FYEWFLRTF ATR FLLPRHPPIF[H/Y]EWFLRTFPDP 
P3_41 HLA-C*04:01 YREQINLTSL FAM20A NRRHKMYREQ[M/I]NLTSLDPPLQ 
P3_42 HLA-C*04:01 SFDSRRFDF FCGBP SGDPHYVSFD[G/S]RRFDFMGTCT 




FHDNLGNSL DLGAP1 QADLDFHDNL[E/G]NSLESIEDNS 




RLDSSSPHTF SDK1 ILGYQIAYRL[A/D]SSSPHTFTTV 
P3_47 HLA-C*04:01 KRDASGSMWL CPAMD8 RQDGSYSAFG[E/K]RDASGSMWLT 
P3_48 HLA-C*04:01 FYTVVTTLL OR4E2 VVSVFYTVVT[P/T]LLNPFIYTLR 
P3_49 HLA-C*08:02 FIEHLTTL HUWE1 EYSFSRHLYS[S/F]IEHLTTLLAS 
P3_50 HLA-C*08:02 FSTNVDLAI HEATR3 EIVLKYLSRF[P/S]TNVDLAISVA 
P3_51 HLA-C*08:02 SVDQSTLLRFL KCNS3 SVDQSTLLRF[P/L]HTRLGKLLTC 
41 
 





































TCRVβ CDR3 Nucleotide Sequence 









































































































I. Supplementary Figures 
 
 
Supplementary Figure 1: Significant antigen-specific expansion of TCR clonotypes to stimulation with HUWE1 MANA-
















































































































































Supplementary Figure 2: Antigen-specific expansion of TCR clonotype (TCRVβ CDR3 sequence: CASSHSGALNTEAFF) to 
SEMA5A MANA-peptide culture (P3_17 peptide). 
 
Supplementary Figure 3: Antigen-specific expansion of TCR clonotype (TCRVβ CDR3 sequence: CASSLALSETNNYGYTF) 






























































































































































































































































































Supplementary Figure 4: Antigen-specific expansion of TCR clonotype (TCRVβ CDR3 sequence: CASSYLTGELFF) to 
DLGAP1 MANA-peptide (P3_44). 
 
Supplementary Figure 5: Antigen-specific expansion of TCR clonotype (TCRVβ CDR3 sequence: CASSYLTGELFF) to 



























































































































































































































































Supplementary Figure 6: Antigen-specific expansion of TCR clonotype (TCRVβ CDR3: CASSLLGGNQPQHF), to TTN 
MANA-peptide (P3_52). 
  
Supplementary Figure 7: Two separate TCR clonotypes (TCRVβ CDR3: Blue circles = CASSVGKGLGTEAFF; Orange 




















































































































































































































































































































































Supplementary Figure 8: Antigen-specific expansion of TCR clonotype (TCRVβ CDR3: CASSPGQSSGNTIYF) to PMEL 
(gp100) peptide (T9). 
  
Supplementary Figure 9: Antigen-specific expansion of TCR clonotype (TCRVβ CDR3: CASSKQGEGEKLFF) to separate 





























































































































































































































































































Supplementary Figure 10: Patient 3 Intratumor T cell TCRVβ Usage. Image adopted from Adaptive Biotechnologies© 
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